July 22, 2019
Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study Development of novel therapeutic agents such as proteasome inhibitors and immunomodulatory drugs (IMiDs), and the combination of these agents with existing therapies, has significantly improved response...
Continue Reading

Floor 7, 90 The Terrace
Wellington Central
New Zealand